The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Gilead Sciences, Inc is $162.00, about 23.5% above its August 3 closing price of $131.15
The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 15 three months ago
Quarterly results beat expectations
US biopharma firm's Q2 product sales rose 8% yr/yr, led by HIV and oncology drugs
Adjusted loss per share for Q2 was lower than analyst expectations
GAAP loss driven by $9.08/share in IPR&D and tax expenses from acquisitions
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Sales
$7.63 bln
Q2 Adjusted Loss Per Share
Beat
$6.75
$7.24 (21 Analysts)
Q2 Loss Per Share
$8.45
Q2 Net Loss
$10.50 bln
HIV and oncology sales drove the quarter
HIV PORTFOLIO GROWTH - Higher sales of HIV products, especially Biktarvy and Descovy, driven by increased demand and higher average realized prices
GILD•
